News from the FDA/CDC

Moderna vaccine more effective than Pfizer and J&J


 

A nationwide study of more than 3,600 adults found the Moderna vaccine does a better job at preventing COVID-19 hospitalizations than the two other vaccines being used in the United States, the Centers for Disease Control and Protection has said.

“Among U.S. adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization during March 11–Aug. 15, 2021, was higher for the Moderna vaccine (93%) than the Pfizer-BioNTech vaccine (88%) and the Janssen vaccine (71%),” the agency’s Morbidity and Mortality Weekly Report said. Janssen refers to the Johnson & Johnson vaccine.

The CDC said the data could help people make informed decisions.

“Understanding differences in VE [vaccine effectiveness] by vaccine product can guide individual choices and policy recommendations regarding vaccine boosters. All Food and Drug Administration–approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization,” the report said.

The study also broke down effectiveness for longer periods. Moderna came out on top again.

After 120 days, the Moderna vaccine provided 92% effectiveness against hospitalization, whereas the Pfizer vaccine’s effectiveness dropped to 77%, the CDC said. There was no similar calculation for the Johnson & Johnson vaccine.

The CDC studied 3,689 adults at 21 hospitals in 18 states who got the two-shot Pfizer or Moderna vaccine or the one-shot Johnson & Johnson vaccine between March and August.

The agency noted some factors that could have come into play.

“Differences in vaccine effectiveness between the Moderna and Pfizer-BioNTech vaccine might be due to higher mRNA content in the Moderna vaccine, differences in timing between doses (3 weeks for Pfizer-BioNTech vs. 4 weeks for Moderna), or possible differences between groups that received each vaccine that were not accounted for in the analysis,” the report said.

The CDC noted limitations in the findings. Children, immunocompromised adults, and vaccine effectiveness against COVID-19 that did not result in hospitalization were not studied.

Other studies have shown all three U.S. vaccines provide a high rate of protection against coronavirus.

A version of this article first appeared on WebMD.com.

Recommended Reading

Even those who just test positive at more risk for long COVID: CDC
MDedge Hematology and Oncology
Biden vaccine mandate rule could be ready within weeks
MDedge Hematology and Oncology
FDA could authorize COVID-19 vaccine for ages 5-11 in October
MDedge Hematology and Oncology
Pandemic strategies to boost trial enrollment should stay
MDedge Hematology and Oncology
COVID wars, part nine: The rise of iodine
MDedge Hematology and Oncology
COVID vaccine preprint study prompts Twitter outrage
MDedge Hematology and Oncology
New Moderna vaccine data ‘support’ booster shot after 8 months
MDedge Hematology and Oncology
‘Empathy fatigue’ in clinicians rises with latest COVID-19 surge
MDedge Hematology and Oncology
FDA panel backs Pfizer's COVID booster for 65 and older, those at high risk
MDedge Hematology and Oncology
COVID vaccine is safe, effective for children aged 5-11, Pfizer says
MDedge Hematology and Oncology